Millennium Management
INKT icon

Millennium Management’s MiNK Therapeutics INKT Stock Holding History

Millennium Management’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,312
Closed -$12.5K – 6276
2024
Q2 		$12.5K Sell
1,312
-698
-35% -$6.79K ﹤0.01% 5583
2024
Q1 		$18.3K Buy
+2,010
New +$18.6K ﹤0.01% 5836
2023
Q1 		– Sell
-1,088
Closed -$28K – 6590
2022
Q4 		$28K Buy
+1,088
New +$25.5K ﹤0.01% 5961
2022
Q1 		– Sell
-6,851
Closed -$306K – 7166
2021
Q4 		$306K Buy
+6,851
New +$815K ﹤0.01% 5519

Other funds holding INKT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management's INKT Position: Q3 2024 in Review

Millennium Management sold out of MiNK Therapeutics (INKT) in Q3 2024, closing a stake of 1,312 shares — an estimated $12.5K sold.

Millennium Management first reported a position in INKT in Q4 2021 and held it in 4 quarters. The position peaked at $306K in Q4 2021. 24 funds tracked by Wall St. Rank hold INKT as of Q3 2024.

  • Millennium Management reported no remaining MiNK Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Millennium Management sold 1,312 MiNK Therapeutics shares in Q3 2024, an estimated $12.5K.
  • Millennium Management first reported a position in MiNK Therapeutics in Q4 2021 and held it in 4 quarters.
  • Millennium Management's MiNK Therapeutics position peaked at $306K in Q4 2021.
  • 24 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q3 2024.

Based on Millennium Management's 13F filing for Q3 2024, filed 14 Nov 2024.